Endovascular Solutions for Ischaemic Cerebrovascular Diseases: Report of the Fifth International Stroke Summit

Z. Zhou,G. Xu,X. Liu

DOI: https://doi.org/10.1111/j.1747-4949.2009.00403.x

2010-01-01

International Journal of Stroke

Abstract:This excellent meeting combined the 6th Asian Pacific Conference Against Stroke and the 20th Stroke Society of Australasia Annual Scientific Meeting. It took place in Cairns between the 6th and 9th of September and succeeded in being more than the sum of its parts. The meeting highlighted the potential for collaboration between the Asia-Pacific region and the rest of the world. An excellent example of this was the CLAIR trial, the primary results of which were reported by Professor Lawrence Wong. This trial compared the effect of clopidogrel1aspirin with aspirin alone on microembolic signal in the first week after stroke. Patients were recruited from Malaysia, Singapore, China and Hong Kong. In a truly international effort, the diffusion-weighted imaging was read in Hong Kong, the transcranial Doppler recordings were read in London and the database was held in Singapore. Results indicated a benefit for the combination treatment in terms of reduced microemboli at day 2 and day 7. A theme that ran throughout the conference was the challenge that exists in developing countries, both in terms of organising stroke care and running stroke research trials. Workshop topics included ‘clinical trials conduct and organisation’, ‘how to be an effective stroke advocate’, ‘academic trials and extending collaborations in Asia’ and ‘setting up stroke services with limited resources’. The predominant feeling was that while there are substantial barriers to stroke care and research in nations such as China and India, there are also remarkable opportunities. Professor Ming Liu, very active in the Cochrane Collaboration, presented a fascinating outline of the current state of stroke research in China. The two keynote speakers, both from the United Kingdom, provided excellent insights on the topical areas of atrial fibrillation and genetics. Professor Richard Hobbs gave a comprehensive update on the latest developments in anticoagulation for the prevention of stroke in patients with atrial fibrillation. Professor Hobbs touched on the potential of direct thrombin inhibitors and indirect factor Xa inhibitors, but also emphasised that warfarin remains a very effective treatment when managed correctly. Professor Hugh Markus presented a thoughtful and realistic assessment of the importance of genetics in stroke. Recent studies on polygenic stroke risk have been made possible by investigating genome-wide associations, but effects found have been small and replication has been difficult. Also involved in the CLAIR trial, Professor Markus spoke about microembolic signal detection in the assessment of stroke risk, and the status of trials investigating aggressive early antiplatelet therapy. A highlight was the workshop on challenges in managing vascular dementia, an often neglected consequence of stroke. The speakers outlined the importance of evaluating cognitive impairment, the role that white matter lesions play in cognition, and the range of treatment options. Another feature of the meeting was the symposium on environmental enrichment in stroke care, a rehabilitation approach that is receiving growing attention. Speakers and panel members discussed the potential for promising results from basic science to be translated into human populations in ‘enriched’ stroke units. Finally, an important milestone was the successful launch of AuSCR, the Australian Stroke Clinical Registry. This new registry is a collaborative national effort to monitor and promote acute stroke care, and data collected will be used to guide quality improvement interventions. After such an interesting conference, we can look forward to SSA 2010, which will be held in Melbourne, Australia from 1 to 3 September 2010.